Tags

Type your tag names separated by a space and hit enter

Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity.
J Travel Med. 2002 May-Jun; 9(3):122-6.JT

Abstract

BACKGROUND

The etiological agents of hepatitis A, hepatitis B, and typhoid fever share similar patterns of global distribution, and cause significant disease burden in travelers to endemic countries. Combined vaccination against all three diseases, based on currently available vaccines, would promote compliance and convenience for travelers. This clinical study evaluated the feasibility of extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and a Vi polysaccharide vaccine (Typherix) in healthy adults, and compared this to concomitant administration of the vaccines in separate arms.

METHODS

The mixed dose of vaccine contained at least 720 enzyme-linked immunosorbent assay (ELISA) units of the inactivated hepatitis A antigen, 20 microg of the recombinant hepatitis B antigen and 25 microg of the Vi polysaccharide typhoid antigen in 1.5 mL. The study was conducted in 200 healthy 18- to 45-year-old volunteers.

RESULTS

Equivalence between the vaccines mixed before administration and the concomitantly administered vaccines was shown in terms of seroconversion and seroprotection. With the exception of local injection site soreness, which was higher in the mixed administration group, the reactogencity was similar for both groups. In both vaccination groups more than 95% of the subjects were anti-hepatitis A virus and anti-Vi seropositive 1 month after the first vaccination. With regard to hepatitis B, a strong response was achieved in both groups, with more than two-thirds of the subjects protected 2 months after the start of the immunization course.

CONCLUSION

These results support the feasibility of extemporaneously syringe-mixed combined hepatitis A and B vaccine with a Vi polysaccharide typhoid vaccine, administered in healthy adults.

Authors+Show Affiliations

Abteilung für Infektions- und Tropenmedizin, Klinikum Innenstadt der Ludwigs-Maximilians-Universität München, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12088576

Citation

Proell, Stephan, et al. "Combined Vaccination Against Hepatitis A, Hepatitis B, and Typhoid Fever: Safety, Reactogenicity, and Immunogenicity." Journal of Travel Medicine, vol. 9, no. 3, 2002, pp. 122-6.
Proell S, Maiwald H, Nothdurft HD, et al. Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. J Travel Med. 2002;9(3):122-6.
Proell, S., Maiwald, H., Nothdurft, H. D., Saenger, R., Vollmar, J., De Clercq, N., & von Sonnenburg, F. (2002). Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. Journal of Travel Medicine, 9(3), 122-6.
Proell S, et al. Combined Vaccination Against Hepatitis A, Hepatitis B, and Typhoid Fever: Safety, Reactogenicity, and Immunogenicity. J Travel Med. 2002 May-Jun;9(3):122-6. PubMed PMID: 12088576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. AU - Proell,Stephan, AU - Maiwald,Hubert, AU - Nothdurft,Hans-Dieter, AU - Saenger,Roland, AU - Vollmar,Jens, AU - De Clercq,Norbert, AU - von Sonnenburg,Frank, PY - 2002/6/29/pubmed PY - 2002/8/22/medline PY - 2002/6/29/entrez SP - 122 EP - 6 JF - Journal of travel medicine JO - J Travel Med VL - 9 IS - 3 N2 - BACKGROUND: The etiological agents of hepatitis A, hepatitis B, and typhoid fever share similar patterns of global distribution, and cause significant disease burden in travelers to endemic countries. Combined vaccination against all three diseases, based on currently available vaccines, would promote compliance and convenience for travelers. This clinical study evaluated the feasibility of extemporaneously syringe-mixed hepatitis A and B vaccine (Twinrix) and a Vi polysaccharide vaccine (Typherix) in healthy adults, and compared this to concomitant administration of the vaccines in separate arms. METHODS: The mixed dose of vaccine contained at least 720 enzyme-linked immunosorbent assay (ELISA) units of the inactivated hepatitis A antigen, 20 microg of the recombinant hepatitis B antigen and 25 microg of the Vi polysaccharide typhoid antigen in 1.5 mL. The study was conducted in 200 healthy 18- to 45-year-old volunteers. RESULTS: Equivalence between the vaccines mixed before administration and the concomitantly administered vaccines was shown in terms of seroconversion and seroprotection. With the exception of local injection site soreness, which was higher in the mixed administration group, the reactogencity was similar for both groups. In both vaccination groups more than 95% of the subjects were anti-hepatitis A virus and anti-Vi seropositive 1 month after the first vaccination. With regard to hepatitis B, a strong response was achieved in both groups, with more than two-thirds of the subjects protected 2 months after the start of the immunization course. CONCLUSION: These results support the feasibility of extemporaneously syringe-mixed combined hepatitis A and B vaccine with a Vi polysaccharide typhoid vaccine, administered in healthy adults. SN - 1195-1982 UR - https://www.unboundmedicine.com/medline/citation/12088576/Combined_vaccination_against_hepatitis_A_hepatitis_B_and_typhoid_fever:_safety_reactogenicity_and_immunogenicity_ L2 - https://academic.oup.com/jtm/article-lookup/doi/10.2310/7060.2002.23845 DB - PRIME DP - Unbound Medicine ER -